Update: Provisional Public Health Service Recommendations for Chemoprophylaxis After Occupational Exposure to HIV

References

1. 1.
   1. CDC

   . Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR 1990;39(no. RR-1).
2. 2.
   1. CDC

   . Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood—France, United Kingdom, and United States, January 1988-August 1994. MMWR 1995;44:929-33.

   Medline
3. 3.
   1. Tokars

   JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993;118:913-9.

   Free Full Text
4. 4.
   1. Connor

   EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.

   CrossRefMedline
5. 5.
   1. Sperling

   RS, Shapiro DE, Coombs R, et al. Maternal plasma HIV-1 RNA and the success of zidovudine in the prevention of mother-child transmission [Abstract no. LB1]. In: Program and abstracts of the 3rd conference on retroviruses and opportunistic infections. Alexandria, Virginia: Infectious Diseases Society of America, 1996.
6. 6.
   1. Niu

   MT, Stein DS, Schnittmann SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment interventions in humans and animal retrovirus infections. J Infect Dis 1993;168:1490-501.

   Free Full Text
7. 7.
   1. Gerberding

   JL. Management of occupational exposures to blood-borne viruses. N Engl J Med 1995;332:444-51.

   CrossRefMedline
8. 8.
   1. Anonymous

   . New drugs for HIV infection. The Medical Letter on Drugs and Therapeutics 1996;38:35-7.

   Medline
9. 9.
   1. Connor

   E, Sperling R, Shapiro D, et al. Long term effect of zidovudine exposure among uninfected infants born to HIV-infected mothers in pediatric AIDS Clinical Trials Group protocol 076. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995;205.
10. 10.
    1. Kinloch-de Loks

    S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333: 408-13.

    CrossRefMedline
11. *.
    The interagency working group comprised representatives of CDC, the Food and Drug Administration (FDA), the Health Resources and Services Administration, and the National Institutes of Health. Information included in these recommendations may not represent FDA approval or approved labeling for the particular products or indications in question. Specifically, the terms "safe" and "effective" may not be synonymous with the FDA-defined legal standards for product approval.
12. †.
    CDC and the National Foundation for Infectious Diseases cosponsored a workshop, HIV Post-Exposure Management for Health Care Workers, on March 4-5, 1996; proceedings of the workshop will be published in the American Journal of Medicine.
13. ‡.
    Single copies of this report will be available free until June 7,1997, from the CDC National AIDS Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003; telephone (800) 458-5231 or (301) 217-0023.
14. §.
    An HIV strain is more likely to be resistant to a specific antiretroviral agent if it is derived from a patient who has been exposed to the agent for a prolonged period of time (e.g., 6-12 months or longer). In general, resistance develops more readily in persons with more advanced HIV infection (e.g., CD4+ T-lymphocyte count of <200 cells/mm3), reflecting the increasing rate of viral replication during later stages of the illness.